entertainment -WSS

entertainment

author：fashion 2025-10-01 01:53:53 - browse：91

The FDA building -- First Opinion coverage from STAT — Adobe

U.S. regulators on Wednesday approved the first treatment for an ultra-rare disease that causes people to grow bone where it otherwise shouldn’t be, extending an option to patients who have been advocating for access to the medicine.

The treatment, an oral medication that will be marketed as Sohonos, faced some questions about the quality of its data, and was rejected earlier this year by European regulators. But in approving the drug for the treatment of fibrodysplasia ossificans progressiva, or FOP, the Food and Drug Administration concluded that Sohonos’ benefits outweigh its risks.

“I just closed my eyes and looked up to the skies, like ‘Thank you, God,’” said Suzanne Hollywood, whose teenage son, Joey, has been receiving the drug in a clinical trial. “It’s far from perfect, but I’m thrilled for my son, for his future, and for the kids getting diagnosed who might not have to experience what others had to.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Infectious disease expert Jeanne Marrazzo assumes Fauci role

focus

WSS

Trump indictment: Who are the 'co

New Alzheimer's drugs heat up race for early detection blood tests

Sage hopes for a blockbuster in antidepressant now before FDA

The haunting brain science of long Covid

National panel will explore requiring free Covid tests

In the gardens at Boston Children's Hospital, families find sanctuary

hotspot

entertainment

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

National panel will explore requiring free Covid tests

Tori Bowie and the unacceptable rates of Black maternal death

In the gardens at Boston Children's Hospital, families find sanctuary

Anesthesiologist group: stop taking Ozempic before surgery

What causes rare myocarditis in young men after Covid vaccines?

Alkermes shareholders re

What to expect as Trump is arraigned on his Jan 6. indictment

Alkermes shareholders re

Physician groups backed by private equity giant lobby on mergers

focus

Why patients can’t get everything they want on drug pricing

Senate panel puts off hardest PBM reforms for another day

The high personal cost of affirmative action for Black doctors

Search called off for baby washed away in Pennsylvania flash flood

UHS says company favors patients whose insurance pays more

Micronoma's microbiome cancer diagnostic approach under fire

hotspot

hotspot

focus

hotspot